Mitigating Toxicity & Revolutionizing Muscle Targeting

The 2nd Gene Therapy for Muscular Disorders Summit will be returning as an in-person event to Boston in April 2022, to help gene therapy developers targeting muscular disorders to overcome safety and toxicity

challenges and effectively translate their programs into the clinic.

Highlighting AAV and gene editing challenges for Duchenne’s (DMD), Limb-Girdle (LGMD), Pompe Disease, X-Linked Myotubular Myopathy and other muscular disorders, this industry-focused 4-day event will cover: 

• Overcoming immunogenicity challenges and mitigate toxicity with high doses
• Optimizing vector and promoter choice and design for more efficient delivery tomuscle targets
• Defining clinically meaningful muscular endpoints to successfully develop and safely deliver the optimal dose to their muscular targets

Join over 150 fellow industry experts to learn, share and benchmark yourselves against your competitors, and overcome the toxicity and dosage challenges hindering the progress of your gene therapy targeting the muscle.

To know more visit: https://ter.li/tbbaua